WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > ABBIOTEC
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Medical
Cytiva, Pall Corporation | June 02, 2021
Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danahe...
Vibe Bio | June 23, 2022
Vibe Biotechnology Inc., a biotechnology company committed to identifying, funding, and developing promising treatments for rare diseases, announced officially launching with $12 million in funding to advance its community-driven approach to transforming drug development for patients with rare diseases. Vibe Bio plans on building a global community of scientists, researchers, patients, and partners with an aim to find cures for rare diseases by efficiently using a decentralized au...
Cell and Gene Therapy, Medical
PRNewswire | May 03, 2023
BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells. BioCentriq, a contract development and manufacturing organization focused exclusively on accelerating the development and manufacturing of ce...
Labiotech.eu | January 27, 2020
Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...
Medical, Industry Outlook
Whitepaper
Video
MedTech
Cell and Gene Therapy
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE